Arginase 1/ARG1/liver Arginase Antibody (ARG1/7514R) [DyLight 405]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-20711V
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry-Paraffin
Label
DyLight 405 (Excitation = 400 nm, Emission = 420 nm)
Antibody Source
Recombinant Monoclonal Rabbit IgG Kappa Clone # ARG1/7514R
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant human Arginase 1/ARG1/liver Arginase protein fragment (aa300-400) (Exact sequence is proprietary)
Localization
Cytoplasm.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Applications for Arginase 1/ARG1/liver Arginase Antibody (ARG1/7514R) [DyLight 405]
Application
Recommended Usage
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Arginase 1/ARG1
Arginase and nitric oxidase synthase (NOS) compete for the same L-arginine substrate, creating a delicate balance between pathways (1). Furthermore, bioavailability of L-arginine and ARG1 expression has been implicated in several pathologies including vascular disease, neuronal disease, cardiovascular disease, immune dysfunction, inflammation, and cancer (1,3-5). For instance, ARG1 functions as a macrophage marker, defining the M2 population, while inducible nitric oxide synthase (iNOS) characterizes the M1 population; impaired M1/M2 polarization and changes in ARG1 expression is observed in diseases such as arteriogenesis, asthma, pulmonary fibrosis, and inflammatory bowel disease (1,3). In humans, arginase deficiency, known as argininemia, is an autosomal recessive metabolic disorder characterized by elevated ammonia (hyperammonemia) levels and arginine accumulation (6). Given that many arginase-associated diseases are characterized by upregulation in expression of ARG1, ARG2, or both, arginase inhibitors are currently being studied as a potential therapeutic approach (1,4).
References
1. S Clemente, G., van Waarde, A., F Antunes, I., Domling, A., & H Elsinga, P. (2020). Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21155291
2. Uniprot (P05089)
3. Kieler, M., Hofmann, M., & Schabbauer, G. (2021). More than just protein building blocks: How amino acids and related metabolic pathways fuel macrophage polarization. The FEBS Journal. Advance online publication. https://doi.org/10.1111/febs.15715
4. Shosha, E., Fouda, A. Y., Narayanan, S. P., Caldwell, R. W., & Caldwell, R. B. (2020). Is the Arginase Pathway a Novel Therapeutic Avenue for Diabetic Retinopathy?. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9020425
5. Correale J. (2021). Immunosuppressive Amino-Acid Catabolizing Enzymes in Multiple Sclerosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.600428
6. Morales, J. A., & Sticco, K. L. (2020). Arginase Deficiency. In StatPearls. StatPearls Publishing.
Long Name
Liver-Type Arginase
Alternate Names
AI, ARG1, Arginase-1, Liver Arginase, PGIF, Type I Arginase
Gene Symbol
ARG1
Additional Arginase 1/ARG1 Products
Product Documents for Arginase 1/ARG1/liver Arginase Antibody (ARG1/7514R) [DyLight 405]
Product Specific Notices for Arginase 1/ARG1/liver Arginase Antibody (ARG1/7514R) [DyLight 405]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...